OUR MUlti-target

Pipeline

We have accelerated our lead 1^st-in-class compound from early discovery to Phase 2 in 2.5 years with seed capital. Using our “Platform-in-a-Mechanism” model, we have built a pipeline across 2 different targets for 3 therapeutic areas. We plan to accelerate 2 additional indications to IND in next 12 months using our super-efficiency model.

Asset 1

GEn-1124 IV
p38α:MK2 Dual Signal Modulators

Pipeline-in-a-Product